The Patent Trials and Appeal Board has ruled in favor of Acorda Therapeutics Inc. (ACOR) by denying inter parties review of the ‘685 patent and ‘826 patent of AMPYRA, the company’s lead drug and a standard of care for improving walking in multiple sclerosis.